To hear about similar clinical trials, please enter your email below

Trial Title: Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT ID: NCT06335914

Condition: Advanced Prostate Cancer

Conditions: Official terms:
Prostatic Neoplasms
Gallium 68 PSMA-11

Conditions: Keywords:
Prostate Specific Membrane Antigen
Positron Emission Tomography

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Diagnostic Test
Intervention name: Ga 68 PSMA-11 PET
Description: Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
Arm group label: PSMA and FDG PET Imaging

Intervention type: Diagnostic Test
Intervention name: 18F-DCFPyL PET
Description: Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
Arm group label: PSMA and FDG PET Imaging

Intervention type: Diagnostic Test
Intervention name: FDG PET
Description: Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
Arm group label: PSMA and FDG PET Imaging

Summary: This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Male, age ≥ 18 years - Histologically or cytologically confirmed prostate cancer (adenocarcinoma) - Poor risk patients with mCSPC at study enrollment - De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI - High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT - Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center. - No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study - Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility Exclusion Criteria: - Under a randomized-controlled trial with unknown allocation of systemic therapy - Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams - Unable to provide written consent by patient and their legal representatives - In the opinion of the treating physician: - conditions which would significantly impair the patient's ability to comply with study procedures and follow up - Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging - another active malignancy - patient on dialysis - another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Princess Margaret Cancer Centre

Address:
City: Toronto
Zip: M5G 2M9
Country: Canada

Contact:
Last name: Di (Maria) Jiang, M.D.

Phone: 416-946-4501

Phone ext: 4807
Email: di.jiang@uhn.ca

Investigator:
Last name: Di (Maria) Jiang, M.D.
Email: Principal Investigator

Start date: September 30, 2024

Completion date: September 4, 2029

Lead sponsor:
Agency: University Health Network, Toronto
Agency class: Other

Source: University Health Network, Toronto

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06335914

Login to your account

Did you forget your password?